The association between mental disorders and treatment retention among people with opioid use disorder receiving opioid agonist treatment: A systematic review and meta-analysis

被引:0
作者
Tran, Lucy T. [1 ]
McKetin, Rebecca [1 ]
Clark, Brodie [1 ]
Macdonald, Christel [1 ]
Zahra, Emma [1 ]
Arunogiri, Shalini [2 ,3 ]
Montebello, Mark E. [1 ,4 ,5 ,6 ]
Degenhardt, Louisa [1 ]
机构
[1] UNSW Sydney, Natl Drug & Alcohol Res Ctr, Sydney, Australia
[2] Monash Univ, Fac Med Nursing & Hlth Sci, Monash Addict Res Ctr, Eastern Hlth Clin Sch, Melbourne, Australia
[3] Eastern Hlth, Turning Point, Melbourne, Vic, Australia
[4] Univ Sydney, Cent Clin Sch, Sydney, NSW, Australia
[5] NSW Minist Hlth, NSW Drug & Alcohol Clin Res & Improvement Network, Sydney, NSW, Australia
[6] North Sydney Local Hlth Dist, Drug & Alcohol Serv, Sydney, NSW, Australia
基金
澳大利亚国家健康与医学研究理事会;
关键词
Opioid use disorder; Opioid agonist treatment; Methadone; Buprenorphine; Mental disorder; Mental health; LONG-TERM RETENTION; PSYCHIATRIC COMORBIDITY; BUPRENORPHINE TREATMENT; TREATMENT OUTCOMES; MAINTENANCE TREATMENT; DEPENDENT PATIENTS; STRESS-DISORDER; METHADONE; IMPACT; TRIAL;
D O I
10.1016/j.drugalcdep.2025.112768
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Background: Mental disorders are common among people with opioid use disorder. This review synthesised evidence of the association of comorbid mental disorders on retention with buprenorphine and methadone treatment. Methods: A systematic search of PubMed, Embase and PsycInfo was conducted in 2025, using search terms related to opioid use disorder and opioid agonist treatment medications of buprenorphine or methadone. Included studies reported on adults aged >= 18 years with opioid use disorder in any treatment setting, measured mental disorders or symptoms of mental disorders and retention in buprenorphine or methadone. Any retention data by mental disorders or symptoms of mental disorders were extracted for analysis. Results: Of 16,056 papers screened, 48 cohorts were included for analyses, consisting of 151,570 individuals. Our meta-analyses indicated that people with mood or personality disorders are more likely to drop out of buprenorphine treatment at 12 and 24 months, compared to people without these specific disorders. At 24 months, people with depression, bipolar disorder, post-traumatic stress disorder, panic disorder and attention-deficit/ hyperactivity disorder are more likely to have ceased buprenorphine treatment, compared to people with no mental disorder. People with psychotic and personality disorders were more likely to be retained in methadone treatment at 24 months compared to either people without these specific disorders or with no mental disorders. Conclusions: Among people who have opioid use disorder, mental disorders are associated with poorer retention in buprenorphine treatment from 6 months. The small number of cohorts within each analysis emphasises a further need for studies examining the association between mental disorders and buprenorphine or methadone retention. This review highlights the importance of clinicians in assessing for comorbid mental disorders to facilitate appropriate long-term care and improve treatment outcomes.
引用
收藏
页数:29
相关论文
共 88 条
[1]   An explainable machine learning framework for predicting the risk of buprenorphine treatment discontinuation for opioid use disorder among commercially insured individuals [J].
Al Faysal J. ;
Noor-E-Alam M. ;
Young G.J. ;
Lo-Ciganic W.-H. ;
Goodin A.J. ;
Huang J.L. ;
Wilson D.L. ;
Park T.W. ;
Hasan M.M. .
Computers in Biology and Medicine, 2024, 177
[2]  
Alford DP, 2011, ARCH INTERN MED, V171, P425, DOI 10.1001/archinternmed.2010.541
[3]  
American Psychiatric Association, 2013, Diagnostic and statistical manual of mental disorders, V5th ed
[4]  
[Anonymous], 2007, Methadone and buprenorphine for the management of opioid dependence
[5]  
[Anonymous], 2018, ICD-11, International Classification of Diseases, V11th
[6]   Safety, Effectiveness and Tolerance of Buprenorphine-Naloxone in the Treatment of Opioid Dependence: Results from a Nationwide Non-Interventional Study in Routine Care [J].
Apelt, S. M. ;
Scherbaum, N. ;
Goelz, J. ;
Backmund, M. ;
Soyka, M. .
PHARMACOPSYCHIATRY, 2013, 46 (03) :94-107
[7]   Mortality among individuals with cannabis, cocaine, amphetamine, MDMA, and opioid use disorders: A nationwide follow-up study of Danish substance users in treatment [J].
Arendt, Mikkel ;
Munk-Jorgensen, Povl ;
Sher, Leo ;
Jensen, Signe O. W. .
DRUG AND ALCOHOL DEPENDENCE, 2011, 114 (2-3) :134-139
[8]   Impact of Co-Occurring Psychiatric Disorders on Retention in a Methadone Maintenance Program: An 18-Month Follow-Up Study [J].
Astals, Monica ;
Diaz, Laura ;
Domingo-Salvany, Antonia ;
Martin-Santos, Rocio ;
Bulbena, Antoni ;
Torrens, Marta .
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH, 2009, 6 (11) :2822-2832
[9]   The influence of coping and depression on abstinence from illicit drug use in methadone-maintained patients [J].
Avants, SK ;
Warburton, LA ;
Margolin, A .
AMERICAN JOURNAL OF DRUG AND ALCOHOL ABUSE, 2000, 26 (03) :399-416
[10]   The effect of person, treatment and prescriber characteristics on retention in opioid agonist treatment: a 15-year retrospective cohort study [J].
Bharat, Chrianna ;
Larney, Sarah ;
Barbieri, Sebastiano ;
Dobbins, Timothy ;
Jones, Nicola R. ;
Hickman, Matthew ;
Gisev, Natasa ;
Ali, Robert ;
Degenhardt, Louisa .
ADDICTION, 2021, 116 (11) :3139-3152